Crescent Biopharma, Inc. (CBIO) Insider Trading
Over the last 3 months, CBIO insiders made 2 open-market buys and 7 sales, a net purchase of $11.1M (SEC Form 4). Over the last 6 months, 33 institutions increased and 16 reduced their position (13F).
Insider Activity
Sentiment
89/100
Buys (3m)
2
Sells (3m)
7
Net (3m)
$11.1M
Insiders buying
Insider trades by month Buys Sells
Jun
Jul
Aug
Dec
Jun
Jul
Context3-month price -11.8%Institutions accumulating (13F)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 20, 2026 | Fairmount Funds Management LLCdirector, 10 percent owner: | Buy | 525,897 | $0.00 |
| Jul 20, 2026 | Fairmount Funds Management LLCdirector, 10 percent owner: | Buy | 853,450 | $14.50 |
| Jun 23, 2026 | Brumm Joshua Tdirector, officer: Chief Executive Officer | Sell | 42,305 | $17.99 |
| Jun 23, 2026 | McNeill Jonathanofficer: President and COO | Sell | 20,549 | $17.99 |
| Jun 23, 2026 | Im Ellie Eunkyungofficer: Chief Medical Officer | Sell | 1,219 | $17.99 |
| Jun 23, 2026 | Bispham Barbara Harlinofficer: See Remarks | Sell | 1,218 | $17.99 |
| Jun 23, 2026 | Scalzo Richard Williamofficer: Chief Financial Officer | Sell | 1,112 | $17.99 |
| Jun 23, 2026 | Pinkas Janofficer: Chief Scientific Officer | Sell | 1,288 | $17.99 |
| Jun 23, 2026 | Lynch Ryanofficer: See Remarks | Sell | 465 | $17.99 |
| Jun 3, 2026 | Fairmount Funds Management LLCdirector, 10 percent owner: | Grant | 11,050 | $17.01 |
| Jun 3, 2026 | Moran Susandirector | Grant | 11,050 | $17.01 |
| Jun 3, 2026 | Violin Jonathandirector | Grant | 11,050 | $17.01 |
| Jun 3, 2026 | Balcom Alexandradirector | Grant | 11,050 | $17.01 |
| Jun 3, 2026 | Lubner David Charlesdirector | Grant | 11,050 | $17.01 |
| Dec 17, 2025 | McNeill Jonathanofficer: President and COO | Grant | 78,029 | $13.21 |
| Dec 17, 2025 | Im Ellie Eunkyungofficer: Chief Medical Officer | Grant | 65,190 | $13.21 |
| Dec 17, 2025 | Im Ellie Eunkyungofficer: Chief Medical Officer | Grant | 5,000 | — |
| Dec 17, 2025 | Im Ellie Eunkyungofficer: Chief Medical Officer | Grant | 16,298 | — |
| Dec 17, 2025 | Lynch Ryanofficer: See Remarks | Grant | 33,512 | $13.21 |
| Dec 17, 2025 | Lynch Ryanofficer: See Remarks | Grant | 4,000 | — |
| Dec 17, 2025 | Lynch Ryanofficer: See Remarks | Grant | 8,378 | — |
| Dec 17, 2025 | Bispham Barbara Harlinofficer: See Remarks | Grant | 72,185 | $13.21 |
| Dec 17, 2025 | Bispham Barbara Harlinofficer: See Remarks | Grant | 6,000 | — |
| Dec 17, 2025 | Bispham Barbara Harlinofficer: See Remarks | Grant | 12,422 | — |
| Dec 17, 2025 | Pinkas Janofficer: Chief Scientific Officer | Grant | 17,507 | — |
| Dec 17, 2025 | Pinkas Janofficer: Chief Scientific Officer | Grant | 5,000 | — |
| Dec 17, 2025 | Pinkas Janofficer: Chief Scientific Officer | Grant | 70,025 | $13.21 |
| Dec 17, 2025 | Doughty Christopher Grantofficer: Chief Business Officer | Grant | 8,000 | — |
| Dec 17, 2025 | Doughty Christopher Grantofficer: Chief Business Officer | Grant | 58,855 | $13.21 |
| Dec 17, 2025 | Doughty Christopher Grantofficer: Chief Business Officer | Grant | 14,714 | — |
Source: CBIO SEC Form 4 filings, latest Jul 20, 2026. For informational purposes only — not investment advice.
Institutional activity (13F)
How institutions changed their CBIO positions over the last 6 months (SEC Form 13F).
Increased
33
New positions
38
Reduced
16
Sold out
26
Largest moves
| Institution | Action | Shares | Filed |
|---|---|---|---|
| FMR LLC | Unchanged | 4.1M | May 15, 2026 |
| FMR LLC | Increased | 4.1M | Feb 17, 2026 |
| BVF INC/IL | Increased | 2.7M | Feb 17, 2026 |
| BVF INC/IL | Unchanged | 2.7M | May 15, 2026 |
| FAIRMOUNT FUNDS MANAGEMENT LLC | Unchanged | 2.7M | May 15, 2026 |
| FAIRMOUNT FUNDS MANAGEMENT LLC | Increased | 2.7M | Feb 17, 2026 |
| VR ADVISER, LLC | Unchanged | 2.1M | May 15, 2026 |
| VR ADVISER, LLC | Increased | 2.1M | Feb 17, 2026 |
| FCPM III SERVICES B.V. | New Position | 1.7M | Feb 17, 2026 |
| FCPM III SERVICES B.V. | Unchanged | 1.7M | May 15, 2026 |
| BALYASNY ASSET MANAGEMENT L.P. | Increased | 1.5M | May 15, 2026 |
| VESTAL POINT CAPITAL, LP | Unchanged | 1.5M | May 15, 2026 |
| VESTAL POINT CAPITAL, LP | New Position | 1.5M | Feb 17, 2026 |
| OPALEYE MANAGEMENT INC. | Reduced | 1.3M | May 15, 2026 |
| OPALEYE MANAGEMENT INC. | New Position | 1.2M | Feb 17, 2026 |
Source: SEC Form 13F filings. For informational purposes only — not investment advice.